$29.66
▲ +0.0% Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript
Overview
52-week range
$11
$32
90% of range
Avg surprise (last 3)
+25.8%
Avg reaction (last 2)
-4.6%
50% positive
Latest IV / EM
60%
EM ±9.4% · $30 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.72 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $-1.02 | $-0.92 | -10.9% | +10.5% | +0.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.27 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | — | $-1.14 | +100.0% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-1.14 | $-1.02 | -11.8% | — | -9.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.00 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.02 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.05 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.94 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.04 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-1.09 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $17M | — | $26M | $160M | $28M | — | $48M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-96M | $-134M | — | $-142M | $-8M | $-122M | — | $-105M |
| Net income | $-91M | $-128M | — | $-135M | $0 | $-112M | — | $-92M |
| EPS (diluted) | $-0.72 | $-1.02 | — | $-1.27 | — | $-1.14 | — | $-1.00 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $150M | $201M | $222M | $238M | $248M | $192M | $150M | $201M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $756M | $844M | $1.01B | $857M | $946M | $1.03B | $1.02B | $1.13B |
| Total assets | $924M | $997M | $1.14B | $974M | $1.07B | $1.16B | $1.15B | $1.25B |
| Long-term debt | $101M | $100M | $99M | $98M | $97M | $48M | $48M | $47M |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $464M | $524M | $631M | $436M | $549M | $531M | $485M | $565M |